Scale Does Not Create Failure, Unmanaged Transitions Do
Cell and gene therapy programs are often described as inherently high-risk due to their complexity. As programs expand across clinical phases, introduce new partners, and operate across multiple sites, it is easy to attribute failure to scale itself. In practice, however, scale is not the root cause of breakdowns. Failures occur at transition points, when systems designed for earlier stages are not structured to support what comes next.
These transitions introduce new custody relationships, new documentation requirements, and new operational dependencies. When governance does not evolve alongside them, gaps begin to form. In cell and gene therapy, those gaps are not easily absorbed. Materials are often patient-specific or otherwise irreplaceable, and a breakdown in chain-of-identity can directly impact patient treatment or invalidate years of development work.
The Role of Chain-of-Identity in CGT Programs
Chain-of-identity is often misunderstood as a tracking function. In regulated CGT environments, it operates as a patient safety system. It establishes a continuous, verifiable linkage between a material and its origin, ensuring that identity is preserved from collection through processing, storage, retrieval, and delivery.
This requirement becomes more complex as programs scale. Materials move between internal teams, CDMOs, clinical sites, and storage providers. Each transition introduces a new point where identity must be preserved and documented. Without a unified framework governing these transitions, the custody record becomes fragmented, and reconstruction becomes necessary.
In regulated environments, reconstruction is not sufficient. Auditors and regulators expect that the chain-of-identity exists as a continuous record, not as something assembled retrospectively.
Where Operational Risk Actually Emerges
The highest-risk points in CGT programs occur during phase transitions. Early-stage programs often operate with manageable volumes and limited partners, allowing for less formalized sample management practices. As programs move-through clinical development phases, the same materials must now meet GMP-aligned documentation standards, traceability requirements, and audit expectations.
At the point where additional clinical sites and multiple manufacturing partners are introduced, the custody network expands. Sample movement increases, retrieval becomes more frequent, and reliance on cell and gene therapy logistics providers grows. Each additional node introduces variability in handling, documentation, and system integration.
Without standardized sample management systems and clearly defined chain-of-custody protocols, inconsistencies begin to accumulate. These inconsistencies may not be immediately visible, but they surface under pressure during regulatory inspections, sponsor audits, or time-sensitive retrieval events.
Storage as a Critical Control Point
Storage is often treated as passive infrastructure within the CGT supply chain. In reality, it functions as one of the most important control points in the system. Materials spend the majority of their lifecycle within controlled environments such as cryogenic storage, ultra-low temperature storage, or GMP storage conditions.
Within these environments, key custody events are recorded. Materials are received, accessioned, quarantined, released, reserved, and retrieved. Each of these actions contributes to the overall custody record. Temperature monitoring and deviation handling further reinforce the integrity of that record.
A temperature excursion, for example, is not only a quality event. It is a documentation event that must be captured, assessed, and resolved with a defensible record. Programs that treat storage as a commodity service rather than a governed function often discover that gaps in storage documentation translate directly into audit exposure.
Documentation That Does Not Scale Becomes a Liability
Many organizations can maintain visibility into their samples. Fewer can produce a complete, audit-ready record of custody events across the full lifecycle of those materials. As programs scale, documentation must shift from being reactive to being structurally complete.
This means that records are generated as a natural outcome of operations, rather than assembled in response to an audit. Chain-of-custody records, inventory status, and retrieval logs must remain consistent across systems, partners, and time.
When documentation depends on manual reconciliation or institutional knowledge, it introduces risk that compounds with scale. Under regulatory scrutiny, the absence of a complete record is itself a finding.
What Scale-Ready Programs Do Differently
Programs that scale successfully approach sample management, storage, and logistics as governed systems rather than operational services. They establish chain-of-identity protocols early, before complexity increases. They implement unified sample management systems that maintain consistency across partners and sites. They align storage and logistics within a framework that produces defensible documentation at every step.
Most importantly, they treat every custody event as part of a permanent record. This approach ensures that when transitions occur the system holds.
Why This Matters
Cell and gene therapy programs do not fail because they grow. They fail when the systems supporting that growth are not designed to scale with them. Transitions expose weaknesses in governance, documentation, and operational control.
Organizations that recognize this early can build infrastructure that supports continuity across the full program lifecycle. Those that do not often encounter these issues under the most challenging conditions—during inspection, submission, or patient-critical operations.
In CGT, the margin for error is minimal. Systems must function as intended, not only during steady-state operations, but especially at the moments when change introduces the greatest risk.
